Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 43

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 43
---
 to appraisal rights in connection with the Merger. Tvardi stockholders are entitled to statutory appraisal rights in connection with the Merger under Section 262 of the DGCL. For more information about such rights, please see the provisions of Section 262 of the DGCL attached as Annex C and the section titled “ The Merger Agreement — Appraisal Rights” beginning on page 188 of this proxy statement/prospectus. Management Following the Merger Immediately following the Merger, the executive management team of the combined company is expected to comprise the following individuals with such additional officers as may be added by the combined company:

| ​                           | ​ | Position with the Combined                            | ​ | ​                                                     |
| Name                        |   | Company                                               |   | Current Position at Tvardi                            |
| Imran Alibhai, Ph.D.        | ​ | Chief Executive Officer and Director                  | ​ | Chief Executive Officer and Director                  |
| Dan Conn, J.D., M.B.A.      | ​ | Chief Financial Officer                               | ​ | Chief Financial Officer                               |
| John Kauh, M.D.             | ​ | Chief Medical Officer                                 | ​ | Chief Medical Officer                                 |
| Jeffrey Larson, Ph.D., DABT | ​ | Senior Vice President, Research & Development         | ​ | Senior Vice President, Research & Development         |
| Yixin “Joseph” Chen, Ph.D.  | ​ | Vice President, Chemistry, Manufacturing and Controls | ​ | Vice President, Chemistry, Manufacturing and Controls |

Directors of the Combined Company Following the Merger At the Effective Time, the combined company is expected to initially have a seven-member board of directors, comprised of five members designated by Tvardi (Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk and Imran Alibhai), one member to be designated by Cara prior to Closing and one vacancy, to be designated by Tvardi if prior to the closing of the Merger or by the combined company if following the consummation of the Merger, until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal. If the one remaining director is not identified prior to the Effective Time, the Combined Company Board anticipates reducing the size of the Combined Company Board to six directors.

<div align='center'>18</div>

The aforementioned Combined Company Board will have an audit committee, a compensation committee and a nominating and corporate governance committee, in accordance with the Nasdaq